Eloxx Pharmaceuticals (NASDAQ:ELOX) Research Coverage Started at Guggenheim

Guggenheim initiated coverage on shares of Eloxx Pharmaceuticals (NASDAQ:ELOX) in a research report released on Monday, MarketBeat.com reports. The firm issued a buy rating and a $43.00 price target on the stock.

Eloxx Pharmaceuticals Stock Performance

Shares of ELOX stock opened at $12.47 on Monday. Eloxx Pharmaceuticals has a 12 month low of $11.42 and a 12 month high of $17.50. The stock has a fifty day simple moving average of $17.31. The company has a market capitalization of $8.60 million, a price-to-earnings ratio of -0.82 and a beta of -1,891.27.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.